Reuters news agency reported on Friday that the government of Argentina has said it received 904,000 doses of Chinese pharmaceutical company Sinopharm's COVID-19 vaccine in its first delivery on 25 February 2021.
Reportedly, this delivery, part of a deal for one million doses of the COVID-19 vaccine, arrived on a plane of Argentina's state carrier from Beijing late in the evening.
According to Argentina's government, the remaining 96,000 remaining doses of the agreement with Sinopharm will arrive in the next few days.
The Foreign Minister of Argentina, Felipe Sola, tweeted: "Everyone is going to get their vaccine and Argentina will be able to move forward."
Reportedly, the Sinopharm COVID-19 vaccines received will add to the 1.22 million doses of Russia's Sputnik V COVID-19 vaccines Argentina has already received, as well as to the 580,000 doses of Covishield, manufactured by the Indian Serum Institute in conjunction with AstraZeneca and Oxford University.
So far, Argentina has recorded over two million cases of COVID-19, with nearly 52,000 deaths.
FDA grants priority review for GSK's gepotidacin gonorrhoea indication
GSK to receive USD370m and future royalties in CureVac/BioNTech settlement
FDA lifts pause on Valneva's chikungunya vaccine IXCHIQ for elderly, updates prescribing information
Anixa Biosciences begins US FDA approved IND transfer to support Phase 2 breast cancer vaccine trial
Pfizer and BioNTech receive EU regulatory backing for LP.8.1-adapted COVID-19 vaccine
Sanofi to acquire Vicebio for USD1.15bn to strengthen respiratory vaccine pipeline
Bavarian Nordic chikungunya vaccine enters Health Canada review process
SK bioscience submits IND for Phase 1/2 clinical trial of new influenza vaccine candidate
GC Biopharma secures Vietnamese approval for varicella vaccine BARYCELA
GSK announces submission of RSV vaccine Arexvy for FDA review
PharmaJet signs MOU with Egyptian UPA and EVA Pharma to introduce needle-free vaccine delivery
Centivax raises USD45m to commercialise universal flu vaccine
CyanVac's nasal COVID vaccine shows promise in phase 1 trial
hVIVO supports Cidara Therapeutics' positive Phase 2b influenza study results